Disc Medicine has achieved a critical milestone in its quest to bring a new therapy for erythropoietic protoporphyria (EPP) to patients. On September 29, 2025, the company submitted an NDA for bitopertin and secured the FDA Commissioner’s National Priority Voucher, a move that could significantly accelerate the drug’s review and potential approval.
Subscribe
Chronic Illness Management
Therapy Options
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business …
Photo by Hastingstribune
Key Takeaways:
- Disc Medicine submitted an NDA for bitopertin to treat EPP.
- The company aims for accelerated approval of this therapy.
- The FDA Commissioner’s National Priority Voucher was awarded, highlighting bitopertin’s importance.
- This voucher is designed to shorten the NDA review period.
- The update was reported on October 20, 2025, underscoring its timely relevance.
Disc Medicine’s NDA Milestone
Disc Medicine announced that on September 29, 2025, it submitted a New Drug Application (NDA) for bitopertin, seeking accelerated approval in the treatment of erythropoietic protoporphyria (EPP). This step underscores the company’s expanding hematology portfolio and ambitions to address a critical patient need.
Significance of the Commissioner’s National Priority Voucher
Disc Medicine has also been awarded the FDA Commissioner’s National Priority Voucher (CNPV). According to the company’s announcement, “the CNPV…shorten(s) the expected NDA review period,” a crucial advantage in bringing therapies to market faster. This highlights the FDA’s focus on promoting treatments that could significantly impact patient care.
Key Milestone Dates
| Date | Milestone |
|---|---|
| September 29, 2025 | NDA submitted for bitopertin in EPP |
| (Award Date Unlisted) | FDA Commissioner’s National Priority Voucher received |
Looking Ahead
By securing the CNPV, Disc Medicine hopes to see a reduced review timeline for bitopertin, potentially accelerating the availability of a new EPP therapy. Although the content available is limited, the announcement marks a notable development in EPP research and highlights the ongoing need for innovative treatments in hematology.
